Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 27, 2003. The document primarily serves as a report of changes in directors' interests and a series of Schedule 5 Blocklisting Six Monthly Returns submitted to the UK Listing Authority. The blocklisting returns cover the period from June 28, 2002, to December 27, 2002.
Key Financial Metrics
The filing does not contain standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial data provided relates to share ownership and equity compensation schemes:
- Total Shares in Issue: 6,024,266,345 (as of the end of the reporting period).
- US Retirement Savings Plan ADRs: Increased to 18,287,511 on January 23, 2003, at an average price of $36.65.
- Share Option Schemes: The filing details the number of shares issued, allotted, and remaining under 12 distinct share option and savings-related schemes.
Material Changes
Material changes reported in this filing are limited to equity movements:
- Directors' Interests: Two directors, Dr. J.P. Garnier and Mr. J.D. Coombe, hold indirect interests in the GlaxoSmithKline US Retirement Savings Plan. The fund's holdings increased by 23,541 ADRs on January 23, 2003, due to fund movements.
- Share Issuances: Various share option schemes saw shares issued or allotted during the six-month period ending December 27, 2002. Notable issuances include:
- Glaxo Group Limited Share Option Scheme: 1,020,069 shares issued.
- Glaxo Wellcome International Share Option Scheme: 673,557 shares issued.
- SmithKline Beecham 1989 US Executive Share Option Plan (Unapproved - ADS): 619,070 shares issued.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, financial guidance, outlook, risk factors, contingencies, or unusual items. The document is strictly administrative regarding share blocklisting and director disclosures.
Investor Verification Checklist
- Verify the total number of shares in issue (6,024,266,345) against the company's latest annual report to ensure consistency.
- Review the specific terms of the 12 share option schemes listed to understand the dilution impact of the shares issued during the period.
- Confirm the indirect ownership structure of directors Dr. J.P. Garnier and Mr. J.D. Coombe within the US Retirement Savings Plan.
- Note that this filing does not contain operational or financial performance data; refer to Form 20-F or interim reports for those metrics.